1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Market Spotlight: Myelofibrosis

Market Spotlight: Myelofibrosis

  • February 2018
  • 30 pages
  • ID: 5182405
  • Format: PDF
  • By Datamonitor Healthcare

Summary

Table of Contents

This Market Spotlight report covers the Myelofibrosis market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
Datamonitor Healthcare estimates that in 2016, there were 46,000 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 57,000 prevalent cases by 2025.
Global prevalence of myelofibrosis is estimated to be 0.0027%.
A majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II. Incyte’s Jakafi (ruxolitinib phosphate) is the only marketed drug for myelofibrosis. It is the first FDA-approved oral JAK1/2 inhibitor for the treatment of the disease.
Therapies in mid- and late-stage development for myelofibrosis focus on targets such as JAK/STAT and hedgehog signaling pathways, FMS-like tyrosine kinase 3, IL-1 receptor-associated kinase 1, histone deacetylase, telomerase, transforming growth factor-beta receptor, Src kinase family, monocytes, interferon receptor, IL-3 receptor, and BCR-ABL fusion protein. The majority of pipeline drugs in mid- to late-stage development for myelofibrosis are administered via the oral route.
High-impact upcoming events for drugs in the myelofibrosis space include pacritinib’s topline Phase III trial results and its expected Committee for Medicinal Products for Human Use (CHMP) opinion.
There were only three licensing agreements during 2013–17. The largest deal during this period was the $1,250m agreement between Bristol-Myers Squibb and Promedior, pursuant to which Bristol-Myers Squibb was granted an exclusive right to acquire Promedior along with its lead asset PRM-151, which is in development for idiopathic pulmonary fibrosis and myelofibrosis.
The clinical trials distribution across Phase I–IV indicates that the majority of trials for myelofibrosis have been in early and midphases of development, with 89% of trials in Phase I–II, and only 11% in Phase III–IV.
The US has a substantial lead in the number of myeloproliferative neoplasm clinical trials globally, yet the forecasted prevalent cases of myelofibrosis are lower in North America as compared with Asia and Europe. Germany leads the major EU markets, while South Korea has the top spot in Asia, where the prevalent cases of myelofibrosis are highest.
Clinical trial activity in the myeloproliferative neoplasms space is dominated by completed trials. Novartis has the highest number of completed clinical trials for myeloproliferative neoplasms.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
2020 Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares by Test, Country Volume and Sales Forecasts, Profiles of Leading Competitors, Emerging Tumor Markers, Technology Assessment, Instrumentation Review

2020 Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares by Test, Country Volume and Sales Forecasts, Profiles of Leading Competitors, Emerging Tumor Markers, Technology Assessment, Instrumentation Review

  • $ 4500
  • January 2020

2020 Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares by Test, Country Volume and Sales Forecasts, Profiles of Leading Competitors, Emerging Tumor Markers, Technology Assessment, Instrumentation ...

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020, provides an ...

2020 Global Adenovirus Diagnostics Market: US, Europe, Japan--Supplier Shares, Volume and Sales Segment Forecasts, Innovative Technologies and Tests, Competitive Profiles and Strategies

2020 Global Adenovirus Diagnostics Market: US, Europe, Japan--Supplier Shares, Volume and Sales Segment Forecasts, Innovative Technologies and Tests, Competitive Profiles and Strategies

  • $ 2800
  • January 2020

2020 Global Adenovirus Diagnostics Market: US, Europe, Japan--Supplier Shares, Volume and Sales Segment Forecasts, Innovative Technologies and Tests, Competitive Profiles and StrategiesThe report presents ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on